China SXT Pharmaceuticals is a holding company. Through its subsidiaries, Co. focuses on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces (TCMP). Co. has two types of Advanced TCMP: Directly-Oral TCMP and After-Soaking-Oral TCMP products. Co. produces Fine TCMP products for drug stores and hospitals. Co. manufactures Regular TCMP products for the treatment of various diseases or serving as dietary supplements. Co. has a product-developed portfolio of 19 Advanced TCMP products among which Advanced TCMP products have been commercialized, Fine TCMP products, and Regular TCMP products that address a variety of diseases and medical indications. The SXTC average annual return since 2019 is shown above.
The Average Annual Return on the SXTC average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SXTC average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SXTC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|